BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2005

View Archived Issues

Maruho takes over Farom marketing after Yamanouchi ends agreement

Read More

Phase III Tysabri study in MS meets two-year endpoint

Read More

Enrollment completed in phase II study of avanafil

Read More

Voyager completes phase II Alzheimer's study

Read More

HIF-1alpha inhibitor blocks proliferation of various tumor cells in normoxic and hypoxic conditions

Read More

Inhibition of IL-6 signaling might be a new approach for allergic asthma treatment

Read More

Preclinical data on broad-spectrum antitumor agent BMS-250749

Read More

Orally efficacious MCH-1 receptor antagonist tested for the treatment of obesity

Read More

Ki-8751: Novel antitumor compound from Kirin

Read More

Aastrom expands U.S. Tissue Repair Cells study

Read More

SBIR grant supports Adenosine Therapeutics' Parkinson's efforts

Read More

Long-lasting responses seen in mycosis fungoides patients receiving HuMax-CD4

Read More

First phase I safety study for ASM-8 for asthma

Read More

TQ-1017 receives orphan drug status for HIV-associated neuropathy

Read More

Pentrys prostate cancer study nearing completion of enrollment

Read More

KM-668 enters preclinical testing as radioprotectant

Read More

Amitriptyline studied for painful bladder syndrome and interstitial cystitis

Read More

Duska Therapeutics updates recent developments

Read More

Spotlight on N-palmitoylethanolamide: multiple potential therapeutic effects

Read More

New data on the benefits of AMD-3100 in stem cell transplantation for cancer patients

Read More

Therapeutic benefits of oxypurinol in congestive heart failure

Read More

A 2% green tea extract shows promise in the treatment of papulopustular rosacea

Read More

In vitro data support the broad-spectrum antifungal activity of R-126638

Read More

Novel 5-HT1A receptor antagonists claimed by Wyeth for depression and anxiety

Read More

Merck identifies new mitotic kinesin inhibitors for use in cancer therapy

Read More

Salvat discloses new PPAR receptor modulators

Read More

Novel anti-HCV agents claimed by the Italian researchers

Read More

Novel DPP-IV inhibitors for type 2 diabetes imparted by Fujisawa

Read More

Japan Science and Technology develops fusion protein for atherosclerosis and cancer

Read More

New antibacterial monoclonal antibodies reported by Japan Science and Technology

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing